These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14764276)

  • 1. Are there specific components of the insulin resistance syndrome that predict the increased atherosclerosis seen in type 2 diabetes mellitus?
    Golden SH; Chong R
    Curr Diab Rep; 2004 Feb; 4(1):26-30. PubMed ID: 14764276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications.
    Eschwège E
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S19-27. PubMed ID: 14502097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperinsulinemia and atherosclerosis.
    Standl E
    Clin Invest Med; 1995 Aug; 18(4):261-6. PubMed ID: 8549011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.
    Plutzky J; Viberti G; Haffner S
    J Diabetes Complications; 2002; 16(6):401-15. PubMed ID: 12477625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications.
    Meerarani P; Badimon JJ; Zias E; Fuster V; Moreno PR
    Curr Mol Med; 2006 Aug; 6(5):501-14. PubMed ID: 16918371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues.
    Aguilar-Salinas CA; Mehta R; Rojas R; Gómez-Pérez FJ; Olaiz G; Rull JA
    Curr Diabetes Rev; 2005 May; 1(2):145-58. PubMed ID: 18220590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.
    Bonora E; Targher G; Formentini G; Calcaterra F; Lombardi S; Marini F; Zenari L; Saggiani F; Poli M; Perbellini S; Raffaelli A; Gemma L; Santi L; Bonadonna RC; Muggeo M
    Diabet Med; 2004 Jan; 21(1):52-8. PubMed ID: 14706054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of vascular disease.
    Colwell J
    Diabetes Obes Metab; 2000 Nov; 2 Suppl 2():S19-24. PubMed ID: 11210241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic macrovascular disease: the glucose paradox?
    Libby P; Plutzky J
    Circulation; 2002 Nov; 106(22):2760-3. PubMed ID: 12450998
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on the cardiometabolic syndrome.
    Sowers JR
    Clin Cornerstone; 2001; 4(2):17-23. PubMed ID: 11838324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is central obesity a good predictor of carotid atherosclerosis in Japanese type 2 diabetes with metabolic syndrome?
    Yasuda T; Matsuhisa M; Fujiki N; Sakamoto F; Tsuji M; Fujisawa N; Kimura M; Ishibashi R; Kaneto H; Yamasaki Y; Watarai T; Imano E
    Endocr J; 2007 Dec; 54(5):695-702. PubMed ID: 17785919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
    Trost S; Pratley R; Sobel B
    Curr Diab Rep; 2006 Feb; 6(1):47-54. PubMed ID: 16522281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
    Srikanth S; Deedwania P
    Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment of metabolic syndrome.
    Altabas V
    Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction and the metabolic syndrome.
    McVeigh GE; Cohn JN
    Curr Diab Rep; 2003 Feb; 3(1):87-92. PubMed ID: 12643151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent lipid abnormalities in diabetes; are we approaching the treatment optimally?
    Hitman GA
    Diabet Med; 2011 Nov; 28(11):1281. PubMed ID: 22004300
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes.
    Eckel RH; Wassef M; Chait A; Sobel B; Barrett E; King G; Lopes-Virella M; Reusch J; Ruderman N; Steiner G; Vlassara H
    Circulation; 2002 May; 105(18):e138-43. PubMed ID: 11994264
    [No Abstract]   [Full Text] [Related]  

  • 18. How to transform a metabolic syndrome score into an insulin sensitivity value?
    Hermans MP; Bouenizabila E; Ahn SA; Rousseau MF
    Diabetes Metab Res Rev; 2016 Jan; 32(1):87-94. PubMed ID: 26111860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes and atherosclerosis.
    Donnelly R; Davis KR
    Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S21-30. PubMed ID: 11225756
    [No Abstract]   [Full Text] [Related]  

  • 20. Type 2 diabetes mellitus in adolescence: lipid and cardiovascular risk factors.
    Jones KL; Dewan AK
    Curr Diab Rep; 2003 Jun; 3(3):255-62. PubMed ID: 12762975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.